Phenotypes in pulmonary hypertension
European Respiratory Journal · 2024-09 · 64 (3) · 2301633
DOI: 10.1183/13993003.01633-2023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 04.07.2024. Verfasst von Jason Weatherald und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada weathera@ualberta.ca. Hauptthemen laut MEDLINE: Phenotype, Hypertension, Pulmonary. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 149 Literaturangaben.
Abstract (Originalsprache)
The clinical classification of pulmonary hypertension (PH) has guided diagnosis and treatment of patients with PH for several decades. Discoveries relating to underlying mechanisms, pathobiology and responses to treatments for PH have informed the evolution in this clinical classification to describe the heterogeneity in PH phenotypes. In more recent years, advances in imaging, computational science and multi-omic approaches have yielded new insights into potential phenotypes and sub-phenotypes within the existing clinical classification. Identification of novel phenotypes in pulmonary arterial hypertension (PAH) with unique molecular profiles, for example, could lead to new precision therapies. Recent phenotyping studies have also identified groups of patients with PAH that more closely resemble patients with left heart disease (group 2 PH) and lung disease (group 3 PH), which has important prognostic and therapeutic implications. Within group 2 and group 3 PH, novel phenotypes have emerged that reflect a persistent and severe pulmonary vasculopathy that is associated with worse prognosis but still distinct from PAH. In group 4 PH (chronic thromboembolic pulmonary disease) and sarcoidosis (group 5 PH), the current approach to patient phenotyping integrates clinical, haemodynamic and imaging characteristics to guide treatment but applications of multi-omic approaches to sub-phenotyping in these areas are sparse. The next iterations of the PH clinical classification are likely to reflect several emerging PH phenotypes and improve the next generation of prognostication tools and clinical trial design, and improve treatment selection in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Division of Pulmonary Medicine, University of Alberta, Edmonton, AB, Canada weathera@ualberta.ca.
- Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
- Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
- University of Maryland-Institute for Health Computing, Bethesda, MD, USA.
- Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada.
- Department of Internal Medicine, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Jason Weatherald, Christian Gerges, Laura C Price, Marius M Hoeper, Marc Humbert
Zitieren
APA
Weatherald, J., Hemnes, A. R., Maron, B. A., Mielniczuk, L. M., Gerges, C., Price, L. C., Hoeper, M. M., & Humbert, M. (2024). Phenotypes in pulmonary hypertension. European Respiratory Journal, 64(3), 2301633. https://doi.org/10.1183/13993003.01633-2023
Vancouver
Weatherald J, Hemnes AR, Maron BA, Mielniczuk LM, Gerges C, Price LC, et al. Phenotypes in pulmonary hypertension. European Respiratory Journal. 2024;64(3):2301633. doi:10.1183/13993003.01633-2023
BibTeX
@article{Weatherald2024,
author = {Weatherald, Jason and Hemnes, Anna R and Maron, Bradley A and Mielniczuk, Lisa M and Gerges, Christian and Price, Laura C and Hoeper, Marius M and Humbert, Marc},
title = {Phenotypes in pulmonary hypertension},
journal = {European Respiratory Journal},
year = {2024},
volume = {64},
number = {3},
pages = {2301633},
doi = {10.1183/13993003.01633-2023}
}
EUVIMED